Académie nationale de médecine, 16 rue Bonaparte, 75006 Paris, France | National Referral Center for Rare Neuromuscular DiseasesHôpital Pitié‐Salpêtrière and University Paris ...
KOL Resume for Jean‐Marc Léger
Académie nationale de médecine, 16 rue Bonaparte, 75006 Paris, France
National Referral Center for Rare Neuromuscular DiseasesHôpital Pitié‐Salpêtrière and University Paris VI Paris France
Centre National de Référence Maladies Neuromusculaires Rares, Hôpital Pitié Salpêtrière et Université Paris VI, Paris, France
Hôpitaux universitaires La-Pitié-Salpêtrière - Charles-Foix, centre de référence maladies neuromusculaires, bâtiment Babinski, 75013 Paris, France
Centre de Référence Maladies Neuromusculaires Bâtiment Babinski.
National Reference Center for Rare Neuromuscular Diseases, Groupe Hospitalier Pitrie Salpêtrière and University Paris VI, Paris Cedex 13, France
From the Department of Neurology (T.H.P.D., E.K.V., C.G.F., I.S.J.M.), University Medical Centre Maastricht; Department of Neurology (S.I.v.N., P.A.v.D.), Erasmus Medical Centre Rotterdam, the Netherlands; Department of Neurology (K.C.G.), St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA; Department of Neurology (W.L.V.d.P., N.C.N., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience University Medical Centre Utrecht, the Netherlands; Department of Neurological Sciences (E.N.-O.), Milan University, Humanitas Clinical Institute, Rozzano, Milan, Italy; Department of Neurology (J.M.L.), Hôpital de la Salpêtrière, Paris, France; Department of Neurology (P.Y.K.V.d.B.), Catholique University of Louvain, Belgium; Department of Clinical Neurosciences (G.L.), 3rd Neurology Unit, Milan, Italy; Department of Neurology (V.B., H.K.), Toronto General Hospital, Canada; Department of Neurology (M.P.T.L.), Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; Department of Neurology (J.P.), Centre de Référence des Maladies Neuromusculaires et de la SLA, Hôpital de La Timone, Marseille, France; Department of Neurology (A.J.v.d.K.), Academic Medical Centre, Amsterdam, the Netherlands; Department of Neurology (A.F.H.), London Health Science Center, London, Canada; Department of Neurology (D.R.C.), Johns Hopkins School of Medicine, Baltimore, MD; and Department of Neurology (I.S.J.M.), Spaarne Hospital, Hoofddorp, the Netherlands.
University Hospital Pitié‐Salpêtrière and University Paris VI National Referral Centre for Neuromuscular Diseases Paris France
Boulevard de l'Hopital, /INS;Paris/INS;,/INS; France
Chair Local Organizing Committee
Centre de Référence de Pathologie Neuromusculaire Paris Est
Department of Neurology, Groupe Hospitalier Pitié-Salpetrière, Paris, France;
Consultation de Pathologie Neuromusculaire, Centre de Référence de Paris Est, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
Consultation de Pathologie Neuromusculaire Groupe Hospitalier, Pitié Saltpêtrière, Paris, France
Centre de Référence Maladies Neuromusculaires rares Paris Est, Bâtiment Babinski. Hôpital de la Salpêtrière, 47 bld de l’Hôpital, 75651 Paris, cedex, 13
Centre de Référence Maladies Neuromusculaires Rares Paris Est. Bâtiment Babinski. Hôpital de la Salpêtrière, 47, bld de l’Hôpital, 75651 Paris cedex 13
APHP, Centre de référence de pathologie neuromusculaire Paris-Est, Bâtiment Babinski, Fédération de Neurologie Mazarin, GH Pitié-Salpêtrière, Paris, France
Department of Neurology, Hôpital de la Salpêtriere, Paris, France
Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom
Consultation de Pathologic Neuromusculaire Groupe Hospitalier, Pitie Saltpetriere, France
Centre de Référence des Maladies Neuro-musculaires rares Paris-Est, Hôpital de la Salpêtrière, Paris.
Members of Joint Task Force of the EFNS and the PNS
Groupe Neuropathies Pitié-Salpêtrière, University Hospital La Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris, Cedex 13, France.
Babinski Building, Salpêtrière Hospital, Paris, France
Groupe Neuropathies Périphériques Pitié-Salpêtrière (GNPS), Hôpital de la Pitié-Salpêtrière, Paris
Service d'Explorations Fonctionnelles, Neurologie, Hôpital de la Salpêtrière, Paris, France
Service de Neurologie, Groupe Hospitalier, Paris, France
Fédération de Neurologie, Bâtiment Mazarin, Hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, Paris.
Department of Neurology, Division Mazarin, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris cedex 13, France
Peripheral Neuropathy Group, Salpêtrière Hospital, Paris, France
Service d'Explorations Fonctionnelles Neurologiques, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France
Laboratoire d'Explorations Fonctionelles Neurologie Hôpital de la Salpêtrière, Paris, France.
Laboratoire INSERM U 289 et Service de Neurologie, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, F-75651, Paris, Cedex 13, France
Department of Neurology, Hôpital de la Salpêtrière, Paris, France.
Service d'Explorations Fonctionnelles, Clinique des Maladies du Système Nerveux, Hôpital de la Salpêtrière, 74, Boulevard de l'Hôpital, F-75013, Paris, France
Clinique des Maladies du Système Nerveux, Hôpital de la Salpêtrière, Paris, France.
Laboratoire d'immunochimie, Hôpital Pitié-Salpétrière, Paris, France
Clinique des Maladies du Système Nerveux, Hôpital de la Salpêtrière, Paris.
Jean‐Marc Léger: Influence Statistics
|search etiological diagnosis||#1|
|responder rate completion||#1|
|purely motor diseases||#1|
|aging electromyography humans||#1|
|multifocal mononeuropathies chronic||#1|
|3 chronic forms||#1|
|gm2 striking features||#1|
|predictive criteria response||#1|
|traitement polyneuropathies dysimmunitaires||#1|
|treatment 93 patients||#1|
|firstline treatment corticosteroids||#1|
|immunotherapy small subset||#1|
|immunemediated disorders corticosteroids||#1|
|polyneuropathies multifocal mononeuropathies||#1|
|shortterm longterm responses||#1|
|igm serum antibodies||#1|
|touches upper limbs||#1|
|unsolved frequent association||#1|
|peripheral nerve society||#1|
Open the FULL List in Excel
Prominent publications by Jean‐Marc Léger
Interferon‐α and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis
[ PUBLICATION ]
OBJECTIVE: Hepatitis C virus (HCV)-related vasculitis may involve multiple organs, including the skin, kidneys, and nervous system, and may be life-threatening. Although HCV is increasingly recognized as a cause of systemic vasculitis, limited data are available regarding the optimal treatment of this potentially serious condition. Therefore, we retrospectively analyzed the response to treatment in patients with chronic hepatitis C complicated by systemic vasculitis who had received ...
|Known for Systemic Vasculitis | Ribavirin Treatment | Antiviral Therapy | Hcv Rna | Followup Patients|
Mixed cryoglobulinemia and hepatitis C virus
[ PUBLICATION ]
BACKGROUND: Mixed cryoglobulinemia (MC) is frequently associated with clinical and biological evidence of liver disease and has recently been reported in cases of hepatitis C virus (HCV) infection. The aim of this study was to assess prospectively in a large series of MC patients: (1) the prevalence of HCV markers (anti-HCV antibodies and HCV RNA in serum and cryoprecipitate); (2) the main clinical, biologic and liver histologic features in patients with or without HCV ...
|Known for Mixed Cryoglobulinemia | Patients Hcv | Essential Mc | Hepatitis Antibodies | Rna Serum|
Immunosuppressive treatment for multifocal motor neuropathy
[ PUBLICATION ]
BACKGROUND: Multifocal motor neuropathy is a distinct clinical entity characterised by progressive, predominantly distal, asymmetrical limb weakness and minimal sensory abnormality. The pathognomonic feature of this condition is the presence of multiple partial motor nerve conduction blocks. Controlled trials have demonstrated the efficacy of regular intravenous immunoglobulin infusions. Immunosuppressive agents have been used as primary, second-line or adjunctive agents for its ...
|Known for Multifocal Motor | Immunosuppressive Agents | Treatment Review | Intravenous Immunoglobulin | Randomised Controlled Trials|
Intravenous immunoglobulin therapy in multifocal motor neuropathyA double-blind, placebo-controlled study
[ PUBLICATION ]
We conducted a double-blind, placebo-controlled, study of 19 patients fulfilling eligibility criteria for multifocal motor neuropathy with persistent conduction block. They were enrolled and divided into two groups: those who had never been treated previously with intravenous immunoglobulins (IVIg) (Group 1: 10 patients) and those who presented recurrent symptoms after previously successful treatment with IVIg (Group 2: nine patients). They were randomized prospectively to receive either ...
|Known for Patients Ivig | Multifocal Motor | 3 Months | Mrc Score | Intravenous Immunoglobulin|
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Fe‐d
[ PUBLICATION ]
BACKGROUND: Revision of the guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy, published in 2005, has become appropriate owing to publication of more relevant articles. Most of the new studies focused on small fiber neuropathy (SFN), a subtype of neuropathy for which the diagnosis was first developed through skin biopsy examination. This revision focuses on the use of this technique to diagnose SFN.
METHODS: Task force members searched the Medline database ...
|Known for Skin Biopsy | Peripheral Nerve | Small Fiber | Diagnosis Sfn | Ienf Density|
OBJECTIVE: To relate X-linked Charcot-Marie-Tooth disease (CMTX) phenotypes to gender and type of neuropathy by the study of a large series of CMTX patients with proven Cx32 point mutations.
BACKGROUND: CMTX is an X-linked form of Charcot-Marie-Tooth disease, caused by mutations in the connexin 32 gene. Males are usually more severely affected and have slower nerve conduction velocities than females.
METHODS: Forty-eight patients from 10 families with Cx32 mutations were examined ...
|Known for Connexin 32 Mutations | Tooth Disease | Linked Charcot | Cmtx Patients | 32 Gene|
Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy
[ PUBLICATION ]
BACKGROUND: Increased titres of serum IgM antibodies to GM1 ganglioside are often associated with multifocal motor neuropathy (MMN). Testing for IgM antibodies to other antigens including GM2, the mixture of GM1 and galactocerebroside (GM1/GalC) and the disulfated heparin disaccharide NS6S were reported to increase the sensitivity of antibody testing in MMN even if it is unclear whether the specificity and positive (PPV) or negative predictive value (NPV) for MMN were also ...
|Known for Multifocal Motor | Igm Antibodies | Mmn Patients | Gm1 Galc | Sensitivity Specificity|
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the Europea
[ PUBLICATION ]
Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials and systematic reviews of treatment have been published. The objective is to prepare consensus guidelines on the definition, investigation and treatment of CIDP. Disease experts and a patient representative considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements which were agreed in an ...
|Known for European Federation | Task Force | Chronic Inflammatory | Peripheral Nerve Society | Neurological Societies|
Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summary
[ PUBLICATION ]
Non-systemic vasculitic neuropathy (NSVN) is routinely considered in the differential diagnosis of progressive axonal neuropathies, especially those with asymmetric or multifocal features. Diagnostic criteria for vasculitic neuropathy, classification criteria for NSVN, and therapeutic approaches to NSVN are not standardized. The aim of this guideline was to derive recommendations on the classification, diagnosis, investigation, and treatment of NSVN based on the available evidence and, ...
|Known for Systemic Vasculitic | Neuropathy Nsvn | Peripheral Nerve | Differential Diagnosis | Immunosuppressive Therapy|
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
[ PUBLICATION ]
BACKGROUND: Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis and was effective in experimental autoimmune neuritis in rats, a possible model for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to evaluate the efficacy of fingolimod in delaying disability progression in patients with CIDP who withdrew from currently effective treatments (intravenous immunoglobulin [IVIg] or corticosteroids).
METHODS: This double-blind, ...
|Known for Chronic Inflammatory | Ivig Corticosteroids | Patients Cidp | Controlled Trial | Intravenous Immunoglobulin|
Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot–Marie–Tooth disease
[ PUBLICATION ]
X-linked dominant Charcot-Marie-Tooth (CMTX) disease is a motor and sensory neuropathy caused by mutations in the connexin 32 (CX32) gene. In this study we report the clinical, electrophysiological and genetic features of 93 patients (41 males, 52 females) from 37 unrelated families with CMTX. Age at onset was 15.4 +/- 9.6 years in males (range 1-40 years) and 18.7 +/- 13.1 years in females (range 1-56 years) (P = 0.22) and the duration of disease at the time of examination was 18.3 +/- ...
|Known for Tooth Disease | Females Males | Age Onset | Molecular Genetic | Linked Charcot|
BACKGROUND: Multifocal motor neuropathy is a distinct clinical entity characterised by progressive, predominantly distal, asymmetrical limb weakness and minimal sensory abnormality. The diagnostic feature of this condition is the presence of multiple partial motor nerve conduction blocks. Controlled trials have demonstrated the efficacy of regular intravenous immunoglobulin infusions. Immunosuppressive agents have been used as primary, second-line or adjunctive agents for its treatment. ...
|Known for Multifocal Motor | Immunosuppressive Agents | Intravenous Immunoglobulin | Conduction Block | Randomised Controlled Trials|
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the Europea
[ PUBLICATION ]
BACKGROUND: Consensus guidelines on the definition, investigation, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been previously published in European Journal of Neurology and Journal of the Peripheral Nervous System.
OBJECTIVES: To revise these guidelines.
METHODS: Disease experts, including a representative of patients, considered references retrieved from MEDLINE and Cochrane Systematic Reviews published between August 2004 and July 2009 and ...
|Known for European Federation | Neurological Societies | Peripheral Nerve Society | Chronic Inflammatory | Joint Task Force|
Non‐anti‐MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases
[ PUBLICATION ]
BACKGROUND AND PURPOSE: Some patients within the spectrum of chronic inflammatory demyelinating polyradiculoneuropathies (CIDP) have distal acquired demyelinating symmetric (DADS) neuropathy, usually associated with anti-myelin-associated-glycoprotein (MAG) IgM monoclonal gammopathy. The aim of this retrospective study was to investigate patients with DADS neuropathy without anti-MAG antibodies, and study their response to immunotherapy.
METHODS: Patients were selected on the basis of ...
|Known for Dads Neuropathy | Patients Chronic Inflammatory | Antimag Antibodies | Response Immunotherapy | Laboratory Features|
Lewis-Sumner syndrome (LSS) is a dysimmune peripheral nerve disorder, characterized by a predominantly distal, asymmetric weakness mostly affecting the upper limbs with sensory impairment, and by the presence of multifocal persistent conduction blocks. The nosological position of this neuropathy in relation to multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is still debated. We report the clinical, biological and electrophysiological ...
|Known for Response Treatment | Cidp Lss | Multifocal Motor | Sumner Syndrome | Upper Limb|
Key People For Multifocal Motor
Jean‐Marc Léger:Expert Impact
Concepts for whichJean‐Marc Légerhas direct influence:Multifocal motor, Chronic inflammatory, European federation, Peripheral neuropathy, Motor neuropathy, Peripheral nervous, Intravenous immunoglobulin, Neurological complications.
Jean‐Marc Léger:KOL impact
Concepts related to the work of other authors for whichfor which Jean‐Marc Léger has influence:Chronic inflammatory, Multifocal motor, Intravenous immunoglobulin, Peripheral neuropathy, Neuropathic pain, Small fiber, Plasma exchange.
Is this your profile? Claim your profile Copy URL Embed Link to your profile